Healthcare data and AI platform H1 has raised $40 million in a new funding round led by CVS Health Ventures, with capital earmarked to expand its AI-driven data infrastructure across provider intelligence, healthcare workflow automation, and care navigation.

The investment deepens an existing relationship between the two organisations. CVS Health Ventures has stated the deal aligns with its broader objectives to simplify care access and reduce administrative overhead. The two companies have previously collaborated on an AI model specifically designed to improve provider directory accuracy, a problem that has accumulated significant operational and financial cost across the US healthcare system.

Inaccurate provider directories sit at the centre of a persistent administrative failure in American healthcare. When directory data is fragmented or outdated, the downstream effects include scheduling errors, misrouted referrals, compliance exposure on network adequacy requirements, and wasted administrative resources. These are not edge-case problems. They affect routine interactions between patients, payers, and providers at scale, and the costs are borne across the entire system.

H1's core technology is built around what the company calls the Doctor Graph, a proprietary data network that structures physician identities, clinical and academic expertise, institutional affiliations, and professional relationships into a single queryable infrastructure. The platform is currently used by 85 per cent of the top 20 global pharmaceutical companies and nine out of ten leading US health plans. Its applications span drug development workflows, medical engagement, health plan network management, and patient navigation.

The funding round reflects a broader reorientation in how healthcare organisations are thinking about artificial intelligence. The earlier wave of interest in consumer-facing generative AI tools has given way to more deliberate investment in foundational infrastructure: systems that can clean, manage, and operationalise large and historically unreliable data ecosystems. H1 sits squarely in that category. Its value proposition is not a new application layer but a more reliable substrate for decisions that healthcare organisations are already making.

On its financial position, H1 reports it is operating profitably and projects it will exceed the technology sector's Rule of 40 threshold in 2026, meaning the combined figure of its year-on-year revenue growth rate and profit margin is expected to reach or surpass 40 per cent. That metric is widely used in software and technology investment as a proxy for sustainable commercial health, and reaching it while still in an active growth phase is relatively uncommon.

The deal is a reasonable indicator of where health-tech investment is moving in 2026. Capital is concentrating on integrated, back-end infrastructure companies that address operational interoperability and data quality rather than standalone tools with narrower functionality. For a long time, health systems and payers have gathered vast amounts of information that remains fragmented, inconsistent, or otherwise unreachable when needed for administrative or clinical decisions. Platforms that solve that problem structurally, rather than working around it, are attracting serious institutional interest.

For CVS Health Ventures, the investment fits a pattern of backing companies that address friction within the care delivery and plan administration processes that CVS Health itself operates at considerable scale. A more accurate and interoperable provider data infrastructure has direct implications for Aetna's network management, for MinuteClinic referral workflows, and for the payer-side compliance burden associated with maintaining adequate network directories under regulatory requirements.

H1's trajectory will depend on whether the Doctor Graph can sustain its data quality advantage as the platform scales and as competitors invest in similar infrastructure. The 90 per cent penetration figure among leading US health plans is a strong market position, but it also limits the domestic growth runway for new plan customers. Pharmaceutical and life sciences adoption, along with international expansion, are the more plausible vectors for continued growth at the pace the Rule of 40 projection implies.

‍